摘要
目的综述近年来靶向程序性细胞死亡受体1(programmed cell death 1,PD-1)和程序性细胞死亡配体1(programmed cell death ligand 1,PD-L1)的单克隆抗体、多肽抑制剂、小分子抑制剂,以及癌症疫苗等方面的研究进展。方法以“PD-1”、“PD-L1”、“抑制剂”等为检索词对国内外文献进行查阅,总结了PD-1/PD-L1靶向抑制剂的研究进展。结果目前,PD-1/PD-L1靶向抑制剂包括单克隆抗体、多肽类抑制剂、小分子抑制剂、抗癌疫苗等,它们旨在阻断PD-1/PD-L1相互作用,恢复T细胞活性。结论在靶向PD-1/PD-L1相互作用的抑制剂中,单克隆抗体的发展最快并获得了成功的应用,但其有免疫原性高等不足;多肽类抑制剂、小分子抑制剂和抗癌疫苗虽未得到广泛应用,但其有着免疫原性低,渗透性好等优点,是未来PD-1/PD-L1靶向药物研发的重点。
Objective To review recent research progresses in monoclonal antibodies,peptide inhibitors,small molecule inhibitors and cancer vaccines targeting programmed cell death 1(PD-1)and programmed cell death ligand 1(PD-L1).Methods The key words including“PD-1,PD-L1 and inhibitors”were used to conduct literature search,and the research progresses of PD-1/PD-L1 targeting inhibitors were summarized.Results Currently,PD-1/PD-L1 targeting inhibitors include monoclonal antibodies,peptide inhibitors,small molecule inhibitors,anti-cancer vaccines,aiming to block the PD-1/PD-L1 interaction and to restore T cell activity.Conclusion Among the inhibitors targeting the PD-1/PD-L1 interaction,monoclonal antibodies have achieved the fastest development and successful clinic applications.Although peptide inhibitors,small molecule inhibitors and anti-cancer vaccines have not been widely used,they are the focus of future PD-1/PD-L1 targeted drug development due to their advantages of low immunogenicity and good permeability.
作者
张百灵
成细瑶
黄永棋
苏正定
ZHANG Bailing;CHENG Xiyao;HUANG Yongqi;SU Zhengding(School of Bioengineering and Food,Hubei University of Technology,Wuhan 430068,China)
出处
《沈阳药科大学学报》
CAS
CSCD
北大核心
2022年第7期887-892,共6页
Journal of Shenyang Pharmaceutical University
